Literature DB >> 28000103

Capsule Commentary on Behar et al., Acceptability of Naloxone Co-Prescription Among Primary Care Providers Treating Patients on Long-Term Opioid Therapy for Pain.

William Cheung1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28000103      PMCID： PMC5331016          DOI： 10.1007/s11606-016-3947-0

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  4 in total

1.  The pharmacists' role in the Patient-Centered Medical Home (PCMH): a white paper created by the Health Policy Committee of the Pennsylvania Pharmacists Association (PPA).

Authors:  Hildegarde Berdine; Tanya Dougherty; Jonathan Ference; Kelly Karpa; Jacqueline Klootwyk; Melinda Kozminski; Nicholas Leon; Maria Osborne; Adam C Welch; Vincent J Willey; Andrew Peterson; Lauren A Stanchak; Allen G Whisler
Journal:  Ann Pharmacother       Date:  2012-04-24       Impact factor: 3.154

2.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  MMWR Recomm Rep       Date:  2016-03-18

3.  Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain.

Authors:  Phillip O Coffin; Emily Behar; Christopher Rowe; Glenn-Milo Santos; Diana Coffa; Matthew Bald; Eric Vittinghoff
Journal:  Ann Intern Med       Date:  2016-06-28       Impact factor: 25.391

4.  Acceptability of Naloxone Co-Prescription Among Primary Care Providers Treating Patients on Long-Term Opioid Therapy for Pain.

Authors:  Emily Behar; Christopher Rowe; Glenn-Milo Santos; Diana Coffa; Caitlin Turner; Nina C Santos; Phillip O Coffin
Journal:  J Gen Intern Med       Date:  2016-11-04       Impact factor: 5.128
  4 in total
  1 in total

1.  Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review.

Authors:  Emily Behar; Rita Bagnulo; Phillip O Coffin
Journal:  Prev Med       Date:  2018-06-15       Impact factor: 4.018
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.